Symbols

ACOG

Alpha Cognition·NASDAQ

--(--)

ACOG fundamentals

ACOG Q4 2025 Earnings

Alpha Cognition (ACOG) released its earnings on Mar 26, 2026: revenue was 3.20M (YoY --), met estimates; EPS was -0.27 (YoY +47.06%), met estimates.

Revenue / YoY

3.20M

EPS / YoY

-0.27

+47.06%

Report date

Mar 26, 2026

ACOG Earnings Call Summary for Q4,2025

Revenue Growth: Q4 net product revenue $2.5M, FY2025 total $10.2M, driven by ZUNVEYL adoption in long-term care.
Payer Expansion: Two major PBMs contracted, with downstream plan implementation expected Q2-Q3 2026.
Clinical Momentum: Three studies (BEACON, CONVERGE, RESOLVE) to validate ZUNVEYL's behavioral benefits and tolerability.
Financial Health: $66M cash, supporting 2026 initiatives and 2027 profitability goal.
Innovation: Sublingual formulation PK study in Q2, targeting dysphagia patients in long-term care.

Earnings

EPS

Revenue

Revenue & Expenses

ACOG has released its 2025 Q3 earnings report, with revenue of 2.84M, reflecting a YoY change of NaN%, and net profit of -1.32M, showing a YoY change of 29.13%. The Sankey diagram below clearly presents ACOG's revenue sources and cost distribution.

Key Indicators

Alpha Cognition (ACOG) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Alpha Cognition (ACOG)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Alpha Cognition (ACOG)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Alpha Cognition (ACOG)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown